Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for ...

An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well ...

A growing body of brain-imaging research has mapped, with increasing precision, how the Amazonian psychedelic brew ayahuasca ...

Scientists are increasingly pointing to everyday ultra-processed foods as a quiet threat to the gut, linking industrial ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

Objectives To investigate the patient-reported outcomes (PROs) and acupuncture-related adverse events (A-AEs) in acupuncture randomised controlled trials (RCTs). Data sources We comprehensively ...

Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study This randomized, parallel-group, phase II study ...